a public good project by the
Synthesis
Company
of California

© 2026

Mario Sznol | doi.page

0 works0 citations0 h-index

Mario Sznol

Yale Cancer Center(US)Yale University(US)

Publications by Year

Research Areas

Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immunotherapy and Immune Responses, Melanoma and MAPK Pathways, Renal cell carcinoma treatment

Most-Cited Works

→ Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer(2012)12,527 cited
→ Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma(2015)8,054 cited
→ Nivolumab plus Ipilimumab in Advanced Melanoma(2013)4,206 cited
→ Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial(2015)2,648 cited
→ Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab(2014)2,197 cited
→ High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993(1999)2,025 cited

→ Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.(1995)

1,373 cited

→ Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma(2018)1,227 cited

→ Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer(2015)1,189 cited

→ Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma(2012)1,178 cited